Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness and safety of clemizole hydrochloride EPX-100 as an additional treatment for children and adults with Dravet syndrome, a rare and severe form of epilepsy. This is a Phase 3, randomized, double-blind, placebo-controlled study conducted across multiple centers. The trial aims to assess whether clemizole HCl can help reduce the number of motor seizures experienced by participants whose seizures are not fully controlled by other anti-epileptic drugs AEDs. Participants will be randomly assigned to receive either clemizole HCl or a matching placebo twice daily during the double-blind phase, which includes a dose titration period followed by a maintenance period lasting up to 16 weeks. Those who complete this phase may have the option to join an open-label extension phase where they will receive clemizole HCl. The investigational treatments are given as oral solutions. Throughout the study, participants will be monitored for changes in the frequency of countable motor seizures over 28-day periods compared to their baseline seizure counts. Other assessments include seizure-free days, use of rescue AEDs, and clinician and caregiver evaluations of improvement. Safety will be closely followed by tracking adverse events. The overall participation may last up to 20 weeks or longer if the optional extension is chosen.
Actively Recruiting
Researchers are evaluating clemizole HCl as an additional treatment for children and adults with Lennox-Gastaut syndrome LGS, a severe form of epilepsy. This phase 3 study is randomized, double-blind, and placebo-controlled, aiming to assess both the safety and effectiveness of clemizole HCl when added to current therapies. The study includes an Observational Period, a Double-Blind Period, and an optional Open-Label Extension Period to gather comprehensive data over time. Participants will be randomly assigned to receive either clemizole HCl or a placebo, both given as oral solutions. After completing the Double-Blind Period, eligible participants may choose to continue treatment with clemizole HCl in the Open-Label Extension Period for up to three years. This design helps researchers compare outcomes between the study drug and placebo, and to observe long-term effects of clemizole HCl. During the study, participants will be monitored regularly to measure changes in seizure frequency and severity, using tools like the CMMS-28 scale. Other assessments include global impression scores from clinicians and caregivers, quality of life evaluations, and safety monitoring for adverse events. The primary outcome focuses on seizure changes over 16 weeks, while secondary outcomes look at seizure-free days, overall impact, and safety throughout the trial duration, potentially spanning up to nearly five years.